Literature DB >> 17996580

Tissue and BAL based biomarkers in asthma.

June Y Zhang1, Sally E Wenzel.   

Abstract

Asthma is a heterogeneous disease with multiple phenotypes. There are no tissue or bronchoalveolar lavage biomarkers that are "specific" for asthma. Markers associated with eosinophilic, neutrophilic, and paucigranulocytic asthma are discussed here, and those for remodeling. Efforts are to compare tissue and lavage biomarkers with less invasive measures, such as sputum, serum, or exhaled breath, to improve the treatment and management of asthma.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17996580     DOI： 10.1016/j.iac.2007.09.003

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN： 0889-8561            Impact factor:   3.479


  14 in total

Review 1.  The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin.

Authors:  Casey T Weaver; Charles O Elson; Lynette A Fouser; Jay K Kolls
Journal:  Annu Rev Pathol       Date:  2012-11-15       Impact factor: 23.472

Review 2.  Paucigranulocytic asthma: Uncoupling of airway obstruction from inflammation.

Authors:  Omar Tliba; Reynold A Panettieri
Journal:  J Allergy Clin Immunol       Date:  2018-06-19       Impact factor: 10.793

3.  [18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation.

Authors:  Delphine L Chen; Timothy J Bedient; James Kozlowski; Daniel B Rosenbluth; Warren Isakow; Thomas W Ferkol; Betsy Thomas; Mark A Mintun; Daniel P Schuster; Michael J Walter
Journal:  Am J Respir Crit Care Med       Date:  2009-07-02       Impact factor: 21.405

4.  A humanized mouse model to study asthmatic airway inflammation via the human IL-33/IL-13 axis.

Authors:  Ryoji Ito; Shuichiro Maruoka; Kaori Soda; Ikumi Katano; Kenji Kawai; Mika Yagoto; Asami Hanazawa; Takeshi Takahashi; Tomoyuki Ogura; Motohito Goto; Riichi Takahashi; Shota Toyoshima; Yoshimichi Okayama; Kenji Izuhara; Yasuhiro Gon; Shu Hashimoto; Mamoru Ito; Satoshi Nunomura
Journal:  JCI Insight       Date:  2018-11-02

Review 5.  Eosinophilic bioactivities in severe asthma.

Authors:  Tara F Carr; Sergejs Berdnikovs; Hans-Uwe Simon; Bruce S Bochner; Lanny J Rosenwasser
Journal:  World Allergy Organ J       Date:  2016-06-27       Impact factor: 4.084

Review 6.  Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?

Authors:  Gilda Varricchi; Gianenrico Senna; Stefania Loffredo; Diego Bagnasco; Matteo Ferrando; Giorgio Walter Canonica
Journal:  Front Immunol       Date:  2017-03-10       Impact factor: 7.561

7.  Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations.

Authors:  David B Price; Sinthia Bosnic-Anticevich; Ian D Pavord; Nicolas Roche; David M G Halpin; Leif Bjermer; Omar S Usmani; Guy Brusselle; Simon Wan Yau Ming; Sarang Rastogi
Journal:  Clin Transl Allergy       Date:  2019-08-21       Impact factor: 5.871

Review 8.  Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.

Authors:  Francesco Menzella; Mirco Lusuardi; Carla Galeone; Sofia Taddei; Luigi Zucchi
Journal:  J Asthma Allergy       Date:  2015-10-08

Review 9.  The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review.

Authors:  Megan F Patterson; Larry Borish; Joshua L Kennedy
Journal:  J Asthma Allergy       Date:  2015-11-03

10.  Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland.

Authors:  Mika J Mäkelä; Helene Nordahl Christensen; Antti Karlsson; Sarang Rastogi; Kirsi Kettunen
Journal:  Eur Clin Respir J       Date:  2018-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.